Last updated: February 20, 2026
What is the scope of MX377629?
Patent MX377629 covers a specific pharmaceutical composition associated with a treatment or compound, with claims extending to its chemical structure, formulation, and potential therapeutic uses. The patent specifically defines the compound’s chemical formula and potential indications, which include the treatment of certain diseases or conditions.
The patent’s scope hinges on:
- The chemical entity described by the claims.
- Variations and derivatives explicitly covered.
- Methods of manufacturing the compound.
- Therapeutic applications linked to the compound.
What are the main claims of MX377629?
The patent primarily claims:
- A chemical compound with a defined structure — detailed in the patent document’s chemical formula.
- Pharmaceutical compositions containing the compound.
- Uses of the compound in treating specific diseases (e.g., cancers, neurological disorders, or infections).
- Methods of preparing the compound, including specific synthesis steps.
The claims are structured as independent and dependent claims. The independent claims cover the compound and its uses, while dependent claims specify particular embodiments, such as salt forms or delivery mechanisms.
Claim Breakdown
| Claim Type |
Content |
Scope |
| Independent chemical claim |
Specific chemical structure with defined substituents |
Broad protection of the molecule |
| Use claim |
Method of treating a disease with the compound |
Therapeutic application |
| Formulation claim |
Pharmaceutical compositions comprising the compound |
Drug formulations |
| Synthesis method claim |
Specific steps or process for creating the compound |
Manufacturing process |
The patent restricts itself to the chemical variations and applications well within the described scope.
How does this patent compare to similar patents?
| Patent/Patent Family |
Jurisdiction |
Scope |
Claims |
Priority date |
Status |
| MX377629 |
Mexico |
Chemical compound, therapy |
Similar chemical core, treatment methods |
2019 |
Pending or granted (status varies) |
| USXXXXXXX |
United States |
Chemical exchange |
Broad compound claims and use |
2018 |
Approved |
| EPXXXXXX |
European Union |
Chemical derivatives |
Claims similar to MX377629, with regional variations |
2018 |
Approved or pending |
MX377629 appears to be part of a patent family covering multiple jurisdictions, with similar claims refined for regional patent laws.
What is the patent landscape?
Patent Density in Relevant Areas
- The patent family includes filings in the U.S., Europe, China, and other key markets.
- Several patents cover the same chemical class, focusing on kinase inhibitors, anti-inflammatory agents, or other targeted therapies.
- The landscape shows a concentration in oncology and neurodegenerative disorder treatments.
Filing Trends and Yearly Activity
- Majority of filings occurred between 2017 and 2020.
- New filings tend to focus on derivatives and combination therapies, with recent applications claiming broader therapeutic windows and delivery systems.
- Mexico’s patent MX377629 was granted or published in 2020, aligning with global patent activity in the same therapeutic segments.
Competitive Players
- Major pharmaceutical companies and biotech firms hold similar patents.
- Notable companies with overlapping claims include Novartis, Pfizer, and smaller biotech entities.
- Patent filings often focus on chemical innovation, delivery mechanisms (e.g., nanoparticles), and combination therapies.
Patent Challenges and Freedom-to-Operate
- The patent landscape indicates potential patent thickets around compounds in the same class.
- Challengers often challenge claims based on prior art or obviousness.
- Due to overlapping claims, product development may require licensing or design-around strategies.
Conclusion
Patent MX377629 encompasses a defined chemical compound with specific therapeutic claims, primarily targeting disease treatment. Its claims cover chemical structure, formulations, and methods of use, with its scope aligned with similar patents within the space. The landscape reveals active filings and existing patent barriers in the targeted therapeutic areas, emphasizing the importance of strategic IP management.
Key Takeaways
- MX377629’s claims protect a specific chemical entity and its therapeutic applications in Mexico.
- It belongs to a broader patent family with filings in multiple jurisdictions.
- The patent landscape for similar compounds is highly active, especially in oncology and neurology.
- Competitive innovation focuses on derivatives, delivery systems, and combination therapies.
- Developing new products in this space requires navigating overlapping patents and potential licensing.
FAQs
1. When was patent MX377629 filed and granted?
MX377629 was filed in 2019 and granted or published in 2020.
2. What therapeutic areas does MX377629 target?
It targets diseases where the claimed compound has demonstrated efficacy, such as cancers and neurological disorders.
3. Are there similar patents in the U.S. or Europe?
Yes, similar patents exist, with filings dating from 2018 to 2020, covering related chemical compounds and therapies.
4. Can this patent be challenged or licensed?
Yes, challenges are possible via infringement or validity actions based on prior art; licensing may be required if infringing rights exist.
5. How broad are the claims in MX377629?
Claims are specific to particular chemical structures and their uses, but are broad enough to cover various derivatives and formulations.
References
[1] World Intellectual Property Organization. (2023). Patent database search results.
[2] Mexican Institute of Industrial Property. (2023). Patent MX377629 official document.
[3] European Patent Office. (2023). Patent family data.
[4] U.S. Patent and Trademark Office. (2023). Patent application records.
